Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Journal: Journal of hematology & oncology
Published: August 11, 2026
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Journal: Journal of hematology & oncology
Published: July 19, 2025
A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Journal: Frontiers in oncology
Published: April 30, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 06, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Journal: Journal for immunotherapy of cancer
Published: October 11, 2024
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: March 15, 2023
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Journal: Cancer chemotherapy and pharmacology
Published: March 13, 2023
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 14, 2023
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Journal: Cancer
Published: October 27, 2022
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.
Journal: Clinical lung cancer
Published: October 23, 2022
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: September 28, 2022
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
Journal: Clinical pharmacology in drug development
Published: July 20, 2022
Last Updated: 09/26/2026